SG

Subhash Gautam

Active Director Director DIN 06746311
DIN 06746311 First appointment Dec 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2013
Shareholding value •••• Premium profile

About Subhash Gautam

Data last updated:

Subhash Gautam is a Director at Wiliance Pharmaceuticals Private Limited (since 2013). The company operates in Pharma. Wiliance Pharmaceuticals Private Limited reported revenue of ₹1.03 Cr (FY 2025).

DIN 06746311
Primary Designation Director
Industry Pharma
First Appointment 17 Dec 2013
Oldest Company Age 12 yrs
Largest company Wiliance Pharmaceuticals Private Limited · ₹1.03 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Dec 20132013₹1.03 Cr (FY 2025)Active

Board colleagues of Subhash Gautam

Directorship timeline

Open interactive timeline →
Wiliance Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Subhash Gautam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Subhash Gautam

Subhash Gautam currently holds 1 directorship: Wiliance Pharmaceuticals Private Limited (Director, since 17 Dec 2013, revenue ₹1.03 Cr (FY 2025)).

Subhash Gautam was first appointed on 17 Dec 2013 as Director at Wiliance Pharmaceuticals Private Limited.

The current boards of Subhash Gautam's companies include Archana Mishra (Wiliance Pharmaceuticals Private Limited), Brijendra Kumar Nigam (Wiliance Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available